Sightera Biosciences

Sightera is a tech-enabled biotech spin-off from the University of Antwerp and Antwerp University Hospital developing novel small molecules through both internal drug discovery programs and strategic partnerships. The company is advancing an in-house pipeline in oncology solid tumors, with a focus on GI-related cancers and fibrotic diseases, including differentiated modalities such as molecular glues, while also supporting pharma partners in expanding their discovery pipelines through asset licensing and platform collaborations. Sightera operates an AI-driven, patient-centric drug discovery platform that combines high-throughput phenotypic screening of patient-derived models (e.g., organoids, microenvironment systems) with deep learning in a lab-in-the-loop workflow. Proprietary drug-response datasets from clinically relevant patient samples are integrated with biomarker identification technologies to define the most relevant patient populations at the start.